Microbiologically confirmed pulmonary Tuberculosis (TB), is the most common and infectious form of tuberculosis and forms the major source of infection in the community.

Every sputum smear-positive patient has the potential to spread the infection to 10 – 15 persons annually, if untreated.

An infectious TB patient becomes a source of infection for all close contacts (household members, workplace coworkers, students studying in the same class or people coming in close contact with such a case).

The district drug-resistant tuberculosis centre (DDR-TBC) committee is a clinical committee where the dean/principal/ director of the institute is the chairperson.

The patient on shorter oral Bedaquiline-containing multi-drug resistant (MDR)/rifampicin resistant TB (RR-TB) regimen shall be put on Type A and Type B box when initiated on treatment on a monthly patient wise box (PWB). Bedaquiline (Bdq) needs to be issued separately and stopped after 6 months. The patient should be provided with only Type A boxes when started on continuation phase (CP).​

Each of the stakeholder plays important role in DR-TB service delivery and has specific responsibility which is being monitored. 

The flow diagram below depicts the processes involved in the delivery of drug-resistant tuberculosis (DR-TB) services and specific functions of various stakeholders.

Figure 1: Cascade of DR-TB services and functions of various stakeholders
Source: Guidelines for PMDT in India, 2021, p.8

​

Figure 1: History of PMDT in India (2007 to 2020).; Source: Guidelines for PMDT in India, 2021 p.02 ​

The Terms of Reference (ToR) for the District DR-TB Centre (DDR-TBC) committee are: